Lumos Diagnostics Holdings Limited (LDX.AX)

AUD 0.04

(5.88%)

Market Cap (In AUD)

26.94 Million

Revenue (In AUD)

11.13 Million

Net Income (In AUD)

-8.59 Million

Avg. Volume

3.02 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.028-0.1075
PE
-
EPS
-
Beta Value
0.78
ISIN
AU0000157091
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Douglas Ward
Employee Count
-
Website
https://lumosdiagnostics.com
Ipo Date
2021-07-05
Details
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.